ATOSSA THERAPEUTICS, INC.
ATOSDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
15dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
How ATOS's past catalysts played out
(Z)-endoxifen
Breast Neoplasms
Topical endoxifen
Mammographic Breast Density
Z-Endoxifen
Breast Density
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
(Z)-endoxifen | Phase 2 | Breast Neoplasms | - | - |
Topical endoxifen | Phase 2 | Mammographic Breast Density | - | - |
Z-Endoxifen | Phase 2 | Breast Density | - | - |
Breast Density
1 drug in this indication
Breast Neoplasms
1 drug in this indication
Mammographic Breast Density
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ATOSSA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ATOSSA THERAPEUTICS, INC.'s (ATOS) pipeline across Phase 2. Its lead program is (Z)-endoxifen (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ATOSSA THERAPEUTICS, INC.'s next FDA catalyst?→
ATOSSA THERAPEUTICS, INC.'s (ATOS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATOS biotech catalysts?→
Add ATOS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ATOSSA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.